Cutting-Edge HEK293T Protein-Integrated Lipid Nanostructures: Boosting Biocompatibility and Efficacy
-
Published:2024-03-14
Issue:6
Volume:25
Page:3294
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Park Jung-Hyun12, Bai Cheng-Zhe3, Kwak Jeong-Hun3, Choi Ho-Joong4, Lee Dosang24, Hong Ha-Eun2, Kim Ok-Hee2, Kim Say-June24
Affiliation:
1. Department of Surgery, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea 2. Catholic Central Laboratory of Surgery, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea 3. Translational Research Team, Surginex Co., Ltd., Seoul 06591, Republic of Korea 4. Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea
Abstract
Recently, artificial exosomes have been developed to overcome the challenges of natural exosomes, such as production scalability and stability. In the production of artificial exosomes, the incorporation of membrane proteins into lipid nanostructures is emerging as a notable approach for enhancing biocompatibility and treatment efficacy. This study focuses on incorporating HEK293T cell-derived membrane proteins into liposomes to create membrane-protein-bound liposomes (MPLCs), with the goal of improving their effectiveness as anticancer therapeutics. MPLCs were generated by combining two key elements: lipid components that are identical to those in conventional liposomes (CLs) and membrane protein components uniquely derived from HEK293T cells. An extensive comparison of CLs and MPLCs was conducted across multiple in vitro and in vivo cancer models, employing advanced techniques such as cryo-TEM (tramsmission electron microscopy) imaging and FT-IR (fourier transform infrared spectroscopy). MPLCs displayed superior membrane fusion capabilities in cancer cell lines, with significantly higher cellular uptake. Additionally, MPLCs maintained their morphology and size better than CLs when exposed to FBS (fetal bovine serum), suggesting enhanced serum stability. In a xenograft mouse model using HeLa and ASPC cancer cells, intravenous administration of MPLCs MPLCs accumulated more in tumor tissues, highlighting their potential for targeted cancer therapy. Overall, these results indicate that MPLCs have superior tumor-targeting properties, possibly attributable to their membrane protein composition, offering promising prospects for enhancing drug delivery efficiency in cancer treatments. This research could offer new clinical application opportunities, as it uses MPLCs with membrane proteins from HEK293T cells, which are known for their efficient production and compatibility with GMP (good manufacturing practice) standards.
Reference26 articles.
1. Li, Y.J., Wu, J.Y., Liu, J., Xu, W., Qiu, X., Huang, S., Hu, X.B., and Xiang, D.X. (2021). Artificial exosomes for translational nanomedicine. J. Nanobiotechnology, 19. 2. Gurunathan, S., Kang, M.H., Jeyaraj, M., Qasim, M., and Kim, J.H. (2019). Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes. Cells, 8. 3. Recent progress in exosome research: Isolation, characterization and clinical applications;Wang;Cancer Gene Ther.,2023 4. Liposomes and polymersomes: A comparative review towards cell mimicking;Rideau;Chem. Soc. Rev.,2018 5. The structural role of cholesterol in cell membranes: From condensed bilayers to lipid rafts;Krause;Acc. Chem. Res.,2014
|
|